Arcturus Therapeutics price to sales ratio ARCT

Market value divided by revenue over the last twelve months, since 2020.

Today, Oct 23, 2026: 9.5×
7-year median: 6.2×
Against its 7-year history: 57th; percentile: 0 is its lowest day, 100 its highest
7-year range: 1.6× to 181×
Peer median: 1.5×

Arcturus Therapeutics' price to sales ratio is 9.5× as of Oct 23, 2026.

That is above its 7-year median of 6.2×, close to the middle of its last 7 years.

Over that time it ranged from 1.6× in Apr 2025 to 181× in Nov 2020.

The median for 10 large drugmakers of a similar size is 1.5×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	9.5×	1.8×	15.5×
2025	1.8×	1.6×	5.0×
2024	2.9×	2.6×	8.4×
2023	2.8×	1.9×	11.3×
2022	8.7×	8.5×	102×
2021	111×	81.8×	175×
2020	103×	8.8×	181×

Against its peers

Companies in Drug Manufacturers - General nearest Arcturus Therapeutics' size, closest first, today.

Company	Price to sales ratio
ARCTArcturus Therapeutics	9.5×
NATRNatures Sunshine Products	0.4×
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	0.9×
ABUSArbutus Biopharma	4.6×
LFVNLifevantage	0.4×
AMPHAmphastar Pharmaceuticals	1.5×
Peer median	1.5×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Arcturus Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.